Diabetic Nephropathy Market Forecast to Boost Growth Globally During 2021-2031
Diabetic nephropathy is the metabolic disorder in which the body has high sugar levels for prolonged period. Diabetes is of two types i.e., type-1 and type-2. Diabetic nephropathy is a medical condition in which diabetes affect kidney and causes chronic kidney diseases and kidney disorders. Diabetic nephropathy is one of the most significant complications, in terms of mortality and morbidity for patients with diabetes. It affects the ability of kidneys to do their usual work of removing waste products and extra fluid from body. The best way to prevent or delay diabetic nephropathy is by maintaining a healthy lifestyle and adequately managing your diabetes and high blood pressure. Kidney disease may progress to kidney failure, also called end-stage kidney disease. Kidney failure is a life-threatening condition. At this stage, treatment options are dialysis or a kidney transplant.
Hypertension or high blood pressure and high cholesterol is a complication of diabetes that is believed to contribute directly to diabetic nephropathy. Therefore, anti-hypertensive drug and anti-hyperlipidemic drug is used to treat diabetic kidney diseases.
Explore More Insights@ https://www.alliedmarketresearch.com/request-sample/16978
Diabetic nephropathy market trends such as discovery and development; launch of various products; and strategies among key players such as acquisition, collaboration, and agreement drive the diabetic nephropathy market. For instance, in 2021, ASTRAZENECA got the approval in Japan and Europe for Forxiga as its key developmental strategy to sustain the intense competition and improve its product portfolio.
Key Market Players
· AbbVie Inc.
· Abbott Laboratories
· Bayer AG
· Eli Lilly and Company
· Merck & Co
· Astrazenica Plc
· Novartis AG
· Pfizer Inc.
· Reata Pharmaceuticals
· Sanofi
The sales of diabetic nephropathy medicine have witnessed hindrances, owing to the strict government regulations on the quality of ingredient and excipients that are used in it. Strict regulatory rules regarding selling and lengthy drug approval times also hamper the market growth. On the contrary, surge in healthcare investments in public as well as private sectors, increase in patient population, and unmet medical demands in developing economies in mostly countries are anticipated to open new avenues for expansion of the diabetic nephropathy market during the forecast period.
Key Benefits:
• Based on product type, the stent segment held the largest share in the U.S. market in 2021 and is expected to remain dominant during the forecast period.
• Based on procedure type, the balloon angioplasty segment held the largest share in the U.S. market in 2021.
• On the basis of application, the cardiology held the largest share in the U.S. market in 2021.
• On the basis of end user, the hospitals segment held the largest share in U.S. market in 2021.
According to a new report published by Allied Market Research, titled, “Diabetic nephropathy Market," The diabetic nephropathy market was valued at $1.9 billion in 2021, and is estimated to reach $3.3 billion by 2031, growing at a CAGR of 6% from 2022 to 2031.
In diabetic nephropathy industry, North America generated maximum revenue in 2021, owing to increase in number of patient admissions and chronic kidney diseases. Asia-Pacific is expected to witness highest CAGR during the forecast period, owing to surge in number of diabetic nephropathy cases, chronic heart disease cases, and increase in prevalence of hypertension.
